Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2024-07-29 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
关于全资子公司产品获得美国FDA上市批准的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the FDA approval of a product by a wholly-owned subsidiary. It contains no financial statements or detailed financial data, nor does it present a report or detailed analysis. The content is an official announcement about a regulatory milestone (FDA approval) and its potential impact on the company. The document length is short (977 characters), and it is clearly an announcement rather than a report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or others that require financial data. It is not a regulatory filing in the sense of compliance or certification, but a specific announcement about product approval. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2024-07-29 Chinese
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of the company's share repurchase program. It details the number of shares repurchased, prices, compliance with regulations, and references previous announcements about the share buyback plan. The document does not contain financial statements or detailed financial analysis but focuses on the update of the share repurchase activity. According to the filing definitions, this fits the category of 'Transaction in Own Shares' (POS), which covers reports of the company buying back its own shares. The document length is short and it is not a report publication announcement or regulatory filing. Therefore, the appropriate classification is POS with high confidence.
2024-07-01 Chinese
关于对下属公司担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 普洛药业股份有限公司 regarding the progress of guarantees provided to its subsidiaries. It details specific guarantee contracts signed with various banks, amounts, terms, and the financial status of the subsidiaries involved. The document includes board opinions and cumulative guarantee amounts. It is a disclosure about financing guarantees rather than a financial report, earnings release, or management discussion. It does not contain financial statements or earnings data but focuses on capital structure-related guarantees. Therefore, it fits best under Capital/Financing Update (CAP). The document length is about 4700 characters, which is sufficient for a detailed announcement rather than a brief notice or report publication announcement.
2024-06-28 Chinese
关于回购股份注销完成暨股份变动的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the completion of a share repurchase cancellation and the resulting changes in the company's share capital. It details the number of shares repurchased and cancelled, the impact on total share capital, and confirms compliance with regulatory requirements. The document does not contain financial statements or detailed financial analysis but serves as a formal disclosure of the share repurchase and cancellation event. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback or sale of its own shares.
2024-06-04 Chinese
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of the company's share repurchase program. It details the number of shares repurchased, prices, compliance with regulations, and future plans for the buyback. It does not contain financial statements or detailed financial analysis but is a regulatory disclosure about the company's transaction in its own shares. Therefore, it fits the category of 'Transaction in Own Shares' (POS). The document length is short and focused solely on the buyback progress, confirming it is not a full financial report or earnings release.
2024-06-03 Chinese
关于对下属公司担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from 普洛药业股份有限公司 regarding the progress of guarantees provided to its subsidiaries. It details specific guarantee contracts signed with banks, amounts, terms, and the financial status of the subsidiaries involved. The document includes board opinions and cumulative guarantee amounts. It is a regulatory announcement about financing guarantees rather than a financial report, earnings release, or management discussion. The document length is 3722 characters, which is relatively short and focused on a specific financing-related update. Therefore, it fits best under Capital/Financing Update (CAP) as it concerns financing guarantees and related contractual information.
2024-05-31 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.